India·Source-based summary

U.S. FDA issues four observations toGland Pharma formulation facility near Hyderabad

The four Form 483 observations followed an unannounced inspection on current good manufacturing practice at the facility in Dundigal between October 12 and 23

This is a source-based summary, not original reporting by Ebenezer journalists. Source: The Hindu. Ebenezer published 24 Oct 2026, 05:38 am. Editorial policy.

India — The Hindu